2003
Discontinuation of Antidepressants in Newly Admitted Psychotic Patients
Bowers MB, McKay BG, Mazure CM. Discontinuation of Antidepressants in Newly Admitted Psychotic Patients. Journal Of Neuropsychiatry 2003, 15: 227-230. PMID: 12724466, DOI: 10.1176/jnp.15.2.227.Peer-Reviewed Original Research
2001
Cortical instability and the mechanism of mania: a neural network simulation and perceptual test
Hoffman R, Quinlan D, Mazure C, McGlashan T. Cortical instability and the mechanism of mania: a neural network simulation and perceptual test. Biological Psychiatry 2001, 49: 500-509. PMID: 11257235, DOI: 10.1016/s0006-3223(00)01071-4.Peer-Reviewed Original ResearchConceptsCognitive speedNeural representationNeural network simulationAuditory continuous performance taskNecker cube perceptionContinuous performance taskSimple perceptual tasksPerceptual tasksPerceptual testsPerformance taskNecker cubeCube taskHuman subject studiesReversal rateCortical noiseSubject studyIndiscriminate responseNormal control subjectsStick figuresTaskSchizophreniaRepresentationNeural networkControl subjectsStimuli
2000
Development and preliminary psychometric properties of an instrument for the measurement of childhood trauma: The early trauma inventory
Bremner J, Vermetten E, Mazure C. Development and preliminary psychometric properties of an instrument for the measurement of childhood trauma: The early trauma inventory. Depression And Anxiety 2000, 12: 1-12. PMID: 10999240, DOI: 10.1002/1520-6394(2000)12:1<1::aid-da1>3.0.co;2-w.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase-Control StudiesChildChild AbuseDepressionFemaleHumansMaleMental DisordersMiddle AgedObserver VariationOdds RatioPanic DisorderPredictive Value of TestsPsychiatric Status Rating ScalesPsychometricsReproducibility of ResultsSchizophreniaStress Disorders, Post-TraumaticTrauma Severity IndicesConceptsEarly Trauma InventoryAbuse/traumaPreliminary psychometric propertiesChildhood traumaTrauma InventoryTraumatic experiencesPsychometric propertiesEarly traumatic experiencesAssessment of traumaGood convergent validityValid instrumentAcceptable inter-rater reliabilityTest-retest reliabilityMeasurement of symptomsSexual abuseConvergent validityComparison subjectsInternal consistencyPTSDInter-rater reliabilityAbuseInventoryTraumaValidityExperience
1999
Olanzapine for Treatment-Refractory Psychosis in Patients Responsive to, but Intolerant of, Clozapine
Weiss E, Longhurst J, Bowers M, Mazure C. Olanzapine for Treatment-Refractory Psychosis in Patients Responsive to, but Intolerant of, Clozapine. Journal Of Clinical Psychopharmacology 1999, 19: 378-380.. PMID: 10440469, DOI: 10.1097/00004714-199908000-00017.Peer-Reviewed Original ResearchSelective Speech Perception Alterations in Schizophrenic Patients Reporting Hallucinated Voices
Hoffman RE, Rapaport J, Mazure CM, Quinlan DM. Selective Speech Perception Alterations in Schizophrenic Patients Reporting Hallucinated Voices. American Journal Of Psychiatry 1999, 156: 393-399. PMID: 10080554, DOI: 10.1176/ajp.156.3.393.Peer-Reviewed Original ResearchConceptsSpeech perceptionSchizophrenia spectrum disordersMasked speechSpectrum disorderAuditory continuous performance taskNeural network computer simulationSentence repetition performanceContinuous performance taskSentence repetition taskNonhallucinating patientsRepetition taskAttentional deficitsAttention impairmentRepetition performancePerformance taskPerception alterationHallucinated voicesMemory systemTaskPerceptionSpeechSchizophrenic patientsNonlanguageDisordersMemory
1998
Management of the Adverse Effects of Clozapine
Young CR, Bowers MB, Mazure CM. Management of the Adverse Effects of Clozapine. Schizophrenia Bulletin 1998, 24: 381-390. PMID: 9718630, DOI: 10.1093/oxfordjournals.schbul.a033333.Peer-Reviewed Original ResearchConceptsAdverse effectsElevated liver enzymesPercent of patientsSuccessful pharmacological managementPositive therapeutic outcomesHypothesized pathophysiologyPharmacological managementRefractory schizophreniaNeuromuscular effectsTraditional neurolepticsLiver enzymesPharmacological interventionsClozapineAffective disordersTherapeutic outcomesNeurological disordersMental disordersMaximum doseObsessive-compulsive symptomsWeight gainDisordersPatientsPathophysiologyNew hopeTreatment
1997
The Expanding Indications for Clozapine
Young C, Longhurst J, Bowers M, Mazure C. The Expanding Indications for Clozapine. Experimental And Clinical Psychopharmacology 1997, 5: 216-234. PMID: 9260069, DOI: 10.1037/1064-1297.5.3.216.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntipsychotic AgentsClozapineHumansMood DisordersNervous System DiseasesSchizophreniaConceptsUnique pharmacodynamic profileUse of clozapineTreatment-resistant schizophreniaTraditional drug treatmentExpanding IndicationsClozapine treatmentNeurologic conditionsPharmacodynamic profileClinical indicationsDrug treatmentMood disordersEffective treatmentClozapineSubstance abuseChildhood schizophreniaRelevant literatureSchizophreniaDisordersTreatmentAggressive behaviorIndicationsInitial rationaleAgranulocytosisPatientsBody of literature
1995
DSM-III-R Axis IV: Clinician Reliability and Comparability to Patients’ Reports of Stressor Severity
Mazure CM, Kincare P, Schaffer CE. DSM-III-R Axis IV: Clinician Reliability and Comparability to Patients’ Reports of Stressor Severity. Psychiatry 1995, 58: 56-64. PMID: 7792323, DOI: 10.1080/00332747.1995.11024711.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdultAgedBipolar DisorderDementiaDepressive DisorderFemaleHumansMaleMiddle AgedPatient AdmissionPersonality AssessmentPsychiatric Status Rating ScalesPsychometricsPsychotic DisordersReproducibility of ResultsRisk FactorsSchizophreniaSchizophrenic PsychologySomatoform DisordersStress, PsychologicalConceptsPsychosocial stressorsAxis IVClinical setting todayMultiaxial diagnostic systemImportant precipitantsExacerbation of psychopathologyPatient reportsPatients' appraisalPsychiatric disordersClinical ratingsClinician reliabilityObjective ratingsSeverityExacerbationStressor severityNosological systemsReportStressorsSubjective appraisalCliniciansAutonomous psychosis following psychotogenic substance abuse
Bowers M, Imirowicz R, Druss B, Mazure C. Autonomous psychosis following psychotogenic substance abuse. Biological Psychiatry 1995, 37: 136-137. PMID: 7718680, DOI: 10.1016/0006-3223(94)00212-l.Peer-Reviewed Original Research
1992
Lithium in combination with perphenazine: effect on plasma monoamine metabolites
Bowers M, Mazure C, Nelson J, Jatlow P. Lithium in combination with perphenazine: effect on plasma monoamine metabolites. Biological Psychiatry 1992, 32: 1102-1107. PMID: 1477190, DOI: 10.1016/0006-3223(92)90190-b.Peer-Reviewed Original ResearchDrug-responsive symptoms during early neuroleptic treatment
Mazure C, Nelson J, Jatlow P, Bowers M. Drug-responsive symptoms during early neuroleptic treatment. Psychiatry Research 1992, 41: 147-154. PMID: 1574541, DOI: 10.1016/0165-1781(92)90106-d.Peer-Reviewed Original ResearchConceptsDrug responseEarly drug responseDays of treatmentIdentification of symptomsNeuroleptic treatmentSerum concentrationsNeuroleptic drugsNeurochemical mechanismsPositive symptomsSymptomsProgressive phaseDrug actionConceptual disorganizationMultiple regression analysisRegression analysisTreatmentPsychosisSeverityHallucinationsResponse
1991
Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis
Mazure C, Nelson J, Jatlow P, Bowers M. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biological Psychiatry 1991, 30: 475-482. PMID: 1932395, DOI: 10.1016/0006-3223(91)90309-a.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultBipolar DisorderChromatography, High Pressure LiquidDepressive DisorderDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHomovanillic AcidHumansMaleMethoxyhydroxyphenylglycolMiddle AgedPerphenazinePrognosisProspective StudiesPsychiatric Status Rating ScalesPsychotic DisordersSchizophreniaSchizophrenic PsychologyConceptsPlasma homovanillic acidHomovanillic acidFree homovanillic acidClinical responseEarly clinical responsePlasma-free homovanillic acidUseful clinical predictorClinical predictorsNeuroleptic treatmentAcute psychosisDopamine metabolismNoradrenergic functioningMethoxyhydroxyphenylglycolFavorable responsePsychotic inpatientsGood responseSignificant decline
1990
The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Mazure CM, Nelson JC, Jatlow PI, Kincare P, Bowers MB. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. The Journal Of Clinical Psychiatry 1990, 51: 330-4. PMID: 2199431.Peer-Reviewed Original ResearchMeSH KeywordsAdultAkathisia, Drug-InducedBasal Ganglia DiseasesBenztropineClinical Trials as TopicDose-Response Relationship, DrugDrug Administration ScheduleFemaleHospitalizationHumansMaleParkinson Disease, SecondaryPerphenazinePsychiatric Status Rating ScalesPsychotic DisordersSchizophreniaSchizophrenic PsychologyConceptsExtrapyramidal side effectsSide effectsBrief Psychiatric Rating Scale (BPRS) totalSerious extrapyramidal side effectsIndividual BPRS itemsResolution of psychosisEarly resolutionBlood level monitoringBlood levelsIndividual symptomsTherapeutic thresholdPsychotic symptomsPsychotic inpatientsScale totalDrug efficacyBPRS itemsPerphenazine concentrationSymptomsPsychosisPerphenazineLevel monitoringPsychotogenic Drug Use and Neuroleptic Response
Bowers MB, Mazure CM, Nelson JC, Jatlow PI. Psychotogenic Drug Use and Neuroleptic Response. Schizophrenia Bulletin 1990, 16: 81-85. PMID: 1970670, DOI: 10.1093/schbul/16.1.81.Peer-Reviewed Original ResearchConceptsDrug useNeuroleptic responseDual diagnosis patientsDoses of haloperidolPsychotic malesDevelopment of psychosisPsychotogenic drugsDiagnosis patientsDopaminergic mechanismsPrior historyPsychotic disordersMeans of effectsRefractorinessSeparate studiesMalesEarly stagesHaloperidolPatientsIllnessPsychosisDoses